Adam D. Durbin

3.4k citations

38 papers · 1.6k indexed · 1 hit paper · h-index 18

Co-authors: A. Thomas Look Brian J. Abraham Richard A. Young Avrum I. Gotlieb David Malkin Takaomi Sanda Mark W. Zimmerman Lee N. Lawton
Topics: Neuroblastoma Research and Treatments (17 papers)Protein Degradation and Inhibitors (11 papers)Sarcoma Diagnosis and Treatment (10 papers)
Cited by: Cancer Research Neurology Molecular Biology
Journals: Science Proceedings of the National Academy of Sciences Angewandte Chemie International Edition
Partner nations: United States Canada United Kingdom

In The Last Decade

Adam D. Durbin

37 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element

2014 538 citations Marc R. Mansour, Brian J. Abraham et al. Science profile →

Peers

Countries citing papers authored by Adam D. Durbin

Since Specialization

Citations

This map shows the geographic impact of Adam D. Durbin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam D. Durbin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam D. Durbin more than expected).

Fields of papers citing papers by Adam D. Durbin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam D. Durbin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam D. Durbin. The network helps show where Adam D. Durbin may publish in the future.

Co-authorship network of co-authors of Adam D. Durbin

This figure shows the co-authorship network connecting the top 25 collaborators of Adam D. Durbin. A scholar is included among the top collaborators of Adam D. Durbin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam D. Durbin. Adam D. Durbin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Myogenesis gone awry: the role of developmental pathways in rhabdomyosarcoma 2025 ·Frontiers in Cell and Developmental Biology ·Annika Gustafson,Adam D. Durbin,Kristin Artinger,Heide L. Ford	3
2	Lineage-Selective Dependencies in Pediatric Cancers 2024 ·Cold Spring Harbor Perspectives in Medicine ·Kristina Ritter,Adam D. Durbin	2
3	Abstract 481: Investigating molecular glues as a new therapeutic approach to high-risk neuroblastoma 2023 ·Cancer Research ·Ian Delahunty,Gisele Nishiguchi,Yang Zhang,(unknown),Anand Mayasundari,Jun Qi,Brian J. Abraham,Anang A. Shelat,Zoran Ranković,Adam D. Durbin	1
4	Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities 2023 ·Nature Structural & Molecular Biology ·Yuxiang Zhang,David Remillard,(unknown),(unknown),Joshua N. Asiaban,(unknown),(unknown),(unknown),(unknown),Stephanie Nance,Adam D. Durbin,Christopher J. Ott,Michalina Janiszewska,Benjamin F. Cravatt,Michael A. Erb	15
5	Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights 2022 ·Cell Reports Medicine ·(unknown),Mark W. Zimmerman,Brian J. Abraham,Adam D. Durbin	10
6	MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation 2021 ·Cancers ·(unknown),Mark W. Zimmerman,Nina Weichert‐Leahey,(unknown),Belamy B. Cheung,Brian J. Abraham,Anneleen Beckers,Pieter‐Jan Volders,Bieke Decaesteker,Daniel R. Carter,(unknown),Katleen De Preter,Wouter Van Loocke,Glenn M. Marshall,Adam D. Durbin,Frank Speleman,Kaat Durinck	9
7	Using Chemical Epigenetics to Target Cancer 2020 ·Molecular Cell ·(unknown),Tingjian Wang,Logan H. Sigua,Adam D. Durbin,Jun Qi	35
8	ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry 2019 ·Nature Communications ·Lu Wang,Tze King Tan,Adam D. Durbin,Mark W. Zimmerman,Brian J. Abraham,Shi Hao Tan,Phuong Cao Thi Ngoc,Nina Weichert‐Leahey,Koshi Akahane,Lee N. Lawton,Jo Lynne Rokita,John M. Maris,Richard A. Young,A. Thomas Look,Takaomi Sanda	54
9	Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors 2019 ·Oncogene ·Dong Hyuk Ki,Felix Oppel,Adam D. Durbin,A. Thomas Look	11
10	Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry 2018 ·Nature Genetics ·Adam D. Durbin,Mark W. Zimmerman,Neekesh V. Dharia,Brian J. Abraham,Amanda Balboni Iniguez,Nina Weichert‐Leahey,Shuning He,John M. Krill-Burger,David E. Root,Francisca Vázquez,Aviad Tsherniak,William C. Hahn,Todd R. Golub,Richard A. Young,A. Thomas Look,Kimberly Stegmaier	145
11	c-MYC drives a subset of high-risk pediatric neuroblastomas and is activated through mechanisms including enhancer hijacking and focal enhancer amplification 2018 ·PMC ·Mark W. Zimmerman,Yu Liu,Shuning He,Adam D. Durbin,Brian J. Abraham,John M. Easton,Ying Shao,Beisi Xu,Shizhen Zhu,Xiaoling Zhang,Zhaodong Li,Nina Weichert‐Leahey,Richard A. Young,Jinghui Zhang,A. Thomas Look	2
12	Diffusion-Weighted Imaging Changes in a Child With Posterior Ischemic Optic Neuropathy 2018 ·Pediatric Neurology ·Dana Harrar,(unknown),Ankoor S. Shah,Jennifer Vaughn,Adam D. Durbin,Michael J. Rivkin	4
13	MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification 2017 ·Cancer Discovery ·Mark W. Zimmerman,Yu Liu,Shuning He,Adam D. Durbin,Brian J. Abraham,John Easton,Ying Shao,Beisi Xu,Shizhen Zhu,Xiaoling Zhang,Zhaodong Li,Nina Weichert‐Leahey,Richard A. Young,Jinghui Zhang,A. Thomas Look	147
14	Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent 2016 ·Pediatric Neurology ·Coral M. Stredny,(unknown),(unknown),Elissa Furutani,Adam D. Durbin,Rachael F. Grace,Nicole J. Ullrich	6
15	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic elementbreakdown → 2014 ·Science ·Marc R. Mansour,Brian J. Abraham,Lars Anders,Alla Berezovskaya,Alejandro Gutiérrez,Adam D. Durbin,Julia Etchin,Lee N. Lawton,Stephen E. Sallan,Lewis B. Silverman,Mignon L. Loh,Stephen P. Hunger,Takaomi Sanda,Richard A. Young,A. Thomas Look	538
16	Recurrent Focal Copy-Number Changes and Loss of Heterozygosity Implicate Two Noncoding RNAs and One Tumor Suppressor Gene at Chromosome 3q13.31 in Osteosarcoma 2010 ·Cancer Research ·Ivan Pašić,Adam Shlien,Adam D. Durbin,Dimitrios J. Stavropoulos,Berivan Baskin,Peter N. Ray,Ana Novokmet,David Malkin	126
17	JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma 2009 ·Journal of Clinical Investigation ·Adam D. Durbin,Gino R. Somers,Michael T. Forrester,Małgorzata Pieńkowska,Gregory E. Hannigan,David Malkin	36
18	Oncogenic ILK, tumor suppression and all that JNK 2009 ·Cell Cycle ·Adam D. Durbin,Gregory E. Hannigan,David Malkin	17
19	The Estrogen Receptor Pathway in Rhabdomyosarcoma: A Role for Estrogen Receptor-β in Proliferation and Response to the Antiestrogen 4′OH-Tamoxifen 2008 ·Cancer Research ·Joshua Greenberg,Stig Sømme,Hege Russnes,Adam D. Durbin,David Malkin	18
20	Nitric oxide promotes in vitro interstitial cell heart valve repair 2005 ·Cardiovascular Pathology ·Adam D. Durbin,(unknown),Alan Rosenthal,Avrum I. Gotlieb	21

About Adam D. Durbin

Adam D. Durbin is a scholar working on Neurology, Immunology and Allergy and Cancer Research, having authored 38 papers that have together received 1.6k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (17 papers), Protein Degradation and Inhibitors (11 papers) and Sarcoma Diagnosis and Treatment (10 papers). The work is most often cited by research in Cancer Research (374 citations), Neurology (348 citations) and Molecular Biology (1.1k citations). Adam D. Durbin has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include A. Thomas Look, Brian J. Abraham, Richard A. Young, Avrum I. Gotlieb, David Malkin, Takaomi Sanda, Mark W. Zimmerman, Lee N. Lawton, Alla Berezovskaya and Alejandro Gutiérrez. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Angewandte Chemie International Edition.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact